Evidence map›Paper›PMID 30924702›Full record

Trial reportJournal of attention disorders2020

A Phase II Double-Blind, Placebo-Controlled, Efficacy and Safety Study of SPN-812 (Extended-Release Viloxazine) in Children With ADHD.

Janet K Johnson, Tesfaye Liranso, Keith Saylor, Gabriela Tulloch, Toyin Adewole, Stefan Schwabe, Azmi Nasser, Robert L Findling, Jeffrey H Newcorn

Abstract readClinical Trial, Phase IIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of attention disorders, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Extended-Release Viloxazine for Children and Adolescents With Attention Deficit Hyperactivity Disorder.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Janet K JohnsonFormerly at Supernus Pharmaceuticals, Inc., Rockville, MD, USA.
Tesfaye LiransoSupernus Pharmaceuticals, Inc., Rockville, MD, USA.
Keith SaylorNeuroScience, Inc., Herndon, VA, USA.
Gabriela TullochFormerly at Supernus Pharmaceuticals, Inc., Rockville, MD, USA.
Toyin AdewoleSupernus Pharmaceuticals, Inc., Rockville, MD, USA.
Stefan SchwabeSupernus Pharmaceuticals, Inc., Rockville, MD, USA.
Azmi NasserSupernus Pharmaceuticals, Inc., Rockville, MD, USA.
Robert L FindlingJohns Hopkins University, Baltimore, MD, USA.
Jeffrey H NewcornIcahn School of Medicine at Mount Sinai, New York, NY, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Attention Deficit Disorder with HyperactivityCentral Nervous System StimulantsViloxazineChildDelayed-Action PreparationsDose-Response Relationship, DrugDouble-Blind MethodHumansTreatment OutcomeCentral Nervous System StimulantsDelayed-Action PreparationsViloxazineADHDattention deficit/hyperactivity disordernonstimulantviloxazine

Identifiers

PMID30924702
PMCPMC6939319

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.